Jianzhijia Pharmaceutical Chain Group Beheer

Beheer criteriumcontroles 4/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Bo Lan

Algemeen directeur

CN¥816.6k

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	23.3%
Management gemiddelde ambtstermijn	3.8yrs
Gemiddelde ambtstermijn bestuur	3.9yrs

Recente managementupdates

Recent updates

CEO

Bo Lan (57 yo)

no data

Tenure

CN¥816,600

Compensatie

Mr. Bo Lan serves as Chairman of the Board and General Manager at Jianzhijia Pharmaceutical Chain Group Co., Ltd. (formerly known as Yunnan Jianzhijia Health-Chain Co., Ltd.).

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Bo Lan	Chairman & GM	no data	CN¥816.60k	23.32% CN¥ 962.4m
Heng Li	CFO, Deputy GM	no data	CN¥464.50k	0.036% CN¥ 1.5m
Yanyin Jiang	Deputy General Manager	3.8yrs	CN¥502.40k	0.17% CN¥ 7.0m
Yanchun Shi	Deputy General Manager	3.8yrs	CN¥818.30k	0.16% CN¥ 6.6m
Yuming Hu	Deputy General Manager	3.8yrs	CN¥254.60k	0.022% CN¥ 894.2k
Fei Yang	Deputy General Manager	1.6yrs	CN¥400.90k	0.026% CN¥ 1.1m
Zhiqi Chai	Deputy General Manager	1.6yrs	CN¥399.50k	0.042% CN¥ 1.7m
Xuejin Song	Accounting Supervisor	no data	geen gegevens	geen gegevens

3.8yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 605266 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Bo Lan	Chairman & GM	no data	CN¥816.60k	23.32% CN¥ 962.4m
Heng Li	CFO, Deputy GM	no data	CN¥464.50k	0.036% CN¥ 1.5m
Yumei Jin	Chairman of the Supervisory Board	3.9yrs	geen gegevens	0.0071% CN¥ 291.7k
Yunhong Guan	Independent Director	3.9yrs	CN¥120.00k	geen gegevens
Li Sun	Supervisor	3.9yrs	geen gegevens	0.0091% CN¥ 373.9k
Li Fang	Supervisor	3.9yrs	geen gegevens	0.0045% CN¥ 185.3k
Weiwen Zhu	Director	3.9yrs	CN¥120.00k	geen gegevens
Liru Yu	Director	3.9yrs	CN¥120.00k	geen gegevens
Fangruo Chen	Independent Director	3.9yrs	CN¥120.00k	geen gegevens
Zhenji Zhao	Independent Director	3.9yrs	CN¥120.00k	geen gegevens

3.9yrs

Gemiddelde duur

52.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 605266 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).

Jianzhijia Pharmaceutical Chain Group Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Jianzhijia Pharmaceutical Chain Group Co., Ltd., Annual General Meeting, May 17, 2024

Jianzhijia Pharmaceutical Chain Group Co., Ltd., Annual General Meeting, May 17, 2024

Less than half of directors are independent

No independent directors

Recent updates

Jianzhijia Pharmaceutical Chain Group Co., Ltd. (SHSE:605266) announces an Equity Buyback for CNY 100 million worth of its shares.

New minor risk - Share price stability

Investor sentiment improves as stock rises 20%

Third quarter 2024 earnings released: EPS: CN¥0.24 (vs CN¥0.78 in 3Q 2023)

Investor sentiment deteriorates as stock falls 16%

Jianzhijia Pharmaceutical Chain Group Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Investor sentiment improves as stock rises 20%

Jianzhijia Pharmaceutical Chain Group Co., Ltd. (SHSE:605266) announces an Equity Buyback for 1,006,711 shares, representing 0.64% for CNY 30 million.

Investor sentiment improves as stock rises 23%

New minor risk - Profit margin trend

Second quarter 2024 earnings released: EPS: CN¥0.069 (vs CN¥0.53 in 2Q 2023)

Investor sentiment deteriorates as stock falls 16%

Jianzhijia Pharmaceutical Chain Group Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Jianzhijia Pharmaceutical Chain Group Co., Ltd. (SHSE:605266) announces an Equity Buyback for CNY 30 million worth of its shares.

Jianzhijia Pharmaceutical Chain Group Co., Ltd., Annual General Meeting, May 17, 2024

First quarter 2024 earnings released: EPS: CN¥0.41 (vs CN¥0.59 in 1Q 2023)

Jianzhijia Pharmaceutical Chain Group Co., Ltd., Annual General Meeting, May 17, 2024

Jianzhijia Pharmaceutical Chain Group Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Investor sentiment improves as stock rises 15%

Jianzhijia Pharmaceutical Chain Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024

Third quarter 2023 earnings released: EPS: CN¥0.94 (vs CN¥0.81 in 3Q 2022)

New minor risk - Financial position

First quarter 2023 earnings released: EPS: CN¥0.77 (vs CN¥0.33 in 1Q 2022)

Investor sentiment improves as stock rises 16%

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥1.06 (vs CN¥0.82 in 3Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.43 (vs CN¥0.94 in 1Q 2021)

No independent directors

Investor sentiment improved over the past week

Yunnan Jianzhijia Health-Chain Co., Ltd. announced that it expects to receive CNY 419.999981 million in funding from Yunnan Xiangqun Investment Co., Ltd

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd